20:33 , Feb 2, 2018 |  BC Week In Review  |  Company News

Seattle Genetics buying Cascadian for $614M

Seattle Genetics Inc. (NASDAQ:SGEN) said it will acquire cancer company Cascadian Therapeutics Inc. (NASDAQ:CASC) for $10 per share in cash, or about $614 million. The price is a 69% premium to Cascadian's close of $5.90...
20:00 , Jan 31, 2018 |  BC Extra  |  Company News

Seattle Genetics buying Cascadian for $614M, raising cash

Seattle Genetics Inc. (NASDAQ:SGEN) said it will acquire cancer company Cascadian Therapeutics Inc. (NASDAQ:CASC) for $10 per share in cash, or about $614 million. The price is a 69% premium to Cascadian's close of $5.90...